A61K 35/763
Herpes virus
A61K35/763 (Herpes virus) appears on 200 US grants and 417 published applications in this corpus.
Search patents in A61K- Granted patents
- 200
- Published applications
- 417
- Assignees
- 183
- Inventors
- 559
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 3 | 8 |
| 2003 | 2 | 5 |
| 2004 | 5 | 10 |
| 2005 | 0 | 8 |
| 2006 | 3 | 5 |
| 2007 | 3 | 7 |
| 2008 | 2 | 9 |
| 2009 | 1 | 9 |
| 2010 | 8 | 7 |
| 2011 | 5 | 15 |
| 2012 | 7 | 10 |
| 2013 | 8 | 11 |
| 2014 | 8 | 7 |
| 2015 | 5 | 12 |
| 2016 | 1 | 9 |
| 2017 | 5 | 14 |
| 2018 | 8 | 18 |
| 2019 | 15 | 33 |
| 2020 | 19 | 44 |
| 2021 | 7 | 31 |
| 2022 | 17 | 45 |
| 2023 | 10 | 28 |
| 2024 | 22 | 24 |
| 2025 | 20 | 27 |
| 2026 | 14 | 21 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer18 Aug 2026US 12,708,653 B2Endeavor Health Clinical Operations
- Stable frozen virus formulation11 Aug 2026US 12,702,688 B2Amgen Inc.
- Oncolytic virus therapy2 Jun 2026US 12,642,832 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Recombinant oncolytic virus, preparation method therefor, use thereof and medicine thereof26 May 2026US 12,636,329 B2
- Oncolytic virus compositions and methods for the treatment of cancer26 May 2026US 12,637,510 B2City of Hope
- Recombinant herpes simplex virus with il-12 expression8 Oct 2026US 2026/0308219 A1
- Oncolytic virus therapy1 Oct 2026US 2026/0294987 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Composition and methods for modulation of elovl224 Sep 2026US 2026/0284154 A1The Regents of the University of California
- Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use24 Sep 2026US 2026/0286317 A1The Brigham and Women S Hospital, Inc.
- Combination of recombinant oncolytic virus and checkpoint inhibitor for the treatment of cancer17 Sep 2026US 2026/0273003 A1Virogin Biotech Canada Ltd
Most cited
By later US patents
- Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject132US 6,428,968 B1The Trustees of the University of Pennsylvania · 2002
- Compositions and methods for regulating production of a precursor protein87US 11,873,505 B2Wyvern Pharmaceuticals Inc. · 2024
- Virus strains63US 7,537,924 B2Biovex Limited · 2009
- Imaging methods and compositions comprising fluorescent dyes associated with viral components for nerve imaging50US 8,361,775 B2Novadaq Technologies Inc. · 2013
- Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth41US 6,723,316 B2Onyx Pharmaceuticals, Inc. · 2004